HPTN 077

A Phase IIa Safety, Tolerability and Acceptability Study of an Investigational Injectable HIV Integrase Inhibitor, GSK1265744, for PrEP in HIV Uninfected Men and Women

Study Summary
Study Documents - Study Details* - Key Study Personnel* - Study SitesPublications
*Authenticated users only (create your account here)

What is HPTN 077?

CAB injectionHPTN 077 is a study being done to learn more about the safety and acceptability of a drug called cabotegravir (sometimes also referred to as GSK 1265744) when taken orally and injected by HIV uninfected men and women. The study product was provided by GlaxoSmithKline on behalf of ViiV Healthcare.

Who is participating in the study?

HPTN 077 enrolled approximately 200 HIV-uninfected men and women in 8 cities: Rio de Janeiro, Brazil; Lilongwe, Malawi; Vulindlela and Soweto, South Africa; Chapel Hill, North Carolina; Los Angeles and San Francisco, California; and Washington, District of Columbia. To enroll in the study, participants had to be deemed low risk for HIV infection, at least 18 years old, and able to provide written informed consent. Enrollment in to the study is completed and follow-up is ongoing.

Why is HPTN 077 important?

HPTN 077 is an important next step in helping to determine if future research should be done to see if injectable cabotegravir can be used for pre-exposure prophylaxis (PrEP) in people at greater risk of acquiring HIV.

What will happen during the study?

Study participants were randomly placed in one of two groups. One group is given pills and injections that has the cabotegravir in it. Approximately seventy-five percent of participants are in this group. The other group is given pills and injections that do not have cabotegravir in it. This is called a placebo. The placebo forms of the drug typically look like the active or “real” drug, but they do not have the drug or any other medicine in them. Approximately twenty-five percent of participants are in this group. The researchers and participants do not know who is getting active drug.

Participants are told that one of the best things they can do to protect themselves from getting HIV and other sexually transmitted infections (like gonorrhea, syphilis or chlamydia) is to use a condom every time they have sex.

Participants will have approximately 19 – 22 study visits over the course of the entire study, which will last for about two years. At these visits the participants receive a physical exam, including checking to see the health of their heart, liver, bones and kidneys, and discuss any concerns or side effects that may be related to the study drugs. All participants receive HIV testing and prevention counseling, as well as condoms at each study visit.

CAB photos

Photos provided by ViiV Healthcare